PE08402008A1 - Methods for managing long lasting hypoglycemic agents - Google Patents

Methods for managing long lasting hypoglycemic agents

Info

Publication number
PE08402008A1
PE08402008A1 PE2007001215A PE0012152007A PE08402008A1 PE 08402008 A1 PE08402008 A1 PE 08402008A1 PE 2007001215 A PE2007001215 A PE 2007001215A PE 0012152007 A PE0012152007 A PE 0012152007A PE 08402008 A1 PE08402008 A1 PE 08402008A1
Authority
PE
Peru
Prior art keywords
methods
long lasting
hypoglycemic agents
managing long
lasting hypoglycemic
Prior art date
Application number
PE2007001215A
Other languages
Spanish (es)
Inventor
Mark A Busch
Jessica E Matthews
Susan E Walker
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US82547206P priority Critical
Priority to US86839106P priority
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE08402008A1 publication Critical patent/PE08402008A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN POLIPEPTIDO QUE TIENE POR LO MENOS UN AGONISTA GLP-1, EL CUAL PROPORCIONA UNA CONCENTRACION MAXIMA DE DICHO POLIPEPTIDO DE 0,6 Nm Y UN AREA BAJO LA CURVA DE 3,5 Nm x DIA APROXIMADAMENTE, DURANTE 1 SEMANA. It refers to a pharmaceutical composition comprising a polypeptide having AT LEAST ONE GLP-1 agonist, which provides a maximum concentration of 0.6 SAID Polypeptide Nm and an area under the curve of 3.5 Nm x day or so, for 1 week. EL AGONISTA DE GLP-1 ES LA HORMONA INCRETINA, COMO FRAGMENTO, CONJUGADO, VARIANTE O MIMETICO DE LA MISMA, LOS CUALES PUEDEN ESTAR FUSIONADOS O NO CON ALBUMINA. Agonist GLP-1 is the hormone incretin as a fragment, conjugate, variant or mimetic thereof, which may be fused or albumin. DICHO COMPUESTO ES UTIL COMO HIPOGLUCEMIANTE SUCH compound is useful as hypoglycemic
PE2007001215A 2006-09-13 2007-09-11 Methods for managing long lasting hypoglycemic agents PE08402008A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US82547206P true 2006-09-13 2006-09-13
US86839106P true 2006-12-04 2006-12-04

Publications (1)

Publication Number Publication Date
PE08402008A1 true PE08402008A1 (en) 2008-08-27

Family

ID=39184534

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007001215A PE08402008A1 (en) 2006-09-13 2007-09-11 Methods for managing long lasting hypoglycemic agents
PE2012001061A PE15282012A1 (en) 2006-09-13 2007-09-11 Methods for managing long lasting hypoglycemic agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2012001061A PE15282012A1 (en) 2006-09-13 2007-09-11 Methods for managing long lasting hypoglycemic agents

Country Status (24)

Country Link
US (3) US8338369B2 (en)
EP (1) EP2073834B1 (en)
JP (2) JP5524620B2 (en)
KR (1) KR101472601B1 (en)
CN (1) CN103705911A (en)
AR (1) AR062775A1 (en)
AU (1) AU2007296499C1 (en)
BR (1) BRPI0716765A2 (en)
CA (1) CA2662622C (en)
CL (1) CL2007002634A1 (en)
CR (1) CR10684A (en)
EA (1) EA017159B1 (en)
ES (1) ES2442869T3 (en)
IL (1) IL197448A (en)
JO (1) JO2945B1 (en)
MA (1) MA30768B1 (en)
MX (1) MX2009002863A (en)
MY (1) MY149911A (en)
NZ (1) NZ575419A (en)
PE (2) PE08402008A1 (en)
SG (2) SG10201501749WA (en)
TW (1) TWI430806B (en)
WO (1) WO2008033888A2 (en)
ZA (1) ZA200901548B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3095456A1 (en) 2005-11-04 2016-11-23 Glaxosmithkline LLC Methods for administering hypoglycemic agents
JP2012511586A (en) * 2008-12-10 2012-05-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC Pharmaceutical compositions
JP2013525491A (en) 2010-05-04 2013-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC How to provide cardiovascular protection to treat or prevent cardiovascular disorders
JP2016519128A (en) * 2013-05-02 2016-06-30 ノヴォ ノルディスク アー/エス Oral dosing of glp-1 compound
AR096440A1 (en) 2013-05-28 2015-12-30 Takeda Pharmaceuticals Co Receptor peptide agonist compound of glucagon-like peptide I (GLP-1) and glucose-dependent insulinotropic peptide (GIP)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE69739172D1 (en) 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation of gastrointestinal mobility
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
JP2002523466A (en) * 1998-08-28 2002-07-30 イーライ・リリー・アンド・カンパニー Method of administration of insulinotropic peptide
EA003922B1 (en) * 1999-05-17 2003-10-30 Конджачем, Инк. Long lasting insulinotropic peptides
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
HU230603B1 (en) * 2000-12-07 2017-03-28 Lilly Co Eli Glp-1 fusion proteins
EP1390061A2 (en) 2000-12-13 2004-02-25 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
WO2002098348A2 (en) * 2001-06-01 2002-12-12 Eli Lilly And Company Glp-1 formulations with protracted time action
HU0501192A3 (en) * 2001-08-23 2006-06-28 Lilly Co Eli Glucagon-like peptide-1 analogs
AR036711A1 (en) 2001-10-05 2004-09-29 Bayer Corp Peptides which act as receptor agonists and glp-1 receptor antagonists of glucagon and their pharmacological use methods
MXPA04003553A (en) 2001-10-18 2004-07-22 Squibb Bristol Myers Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions.
EP2261250B1 (en) * 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc Albumin fusion proteins
AR038102A1 (en) 2002-01-08 2004-12-29 Lilly Co Eli Analogs extended glucagon-like peptide 1
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albumin fusion proteins
EP1743676A1 (en) * 2003-11-12 2007-01-17 Phenomix Corporation Heterocyclic boronic acid derivatives, dipeptidyl peptidase IV inhibitors
EP1704998B1 (en) * 2004-01-13 2011-04-20 Asahi Glass Company, Limited Multilayer laminate
MXPA06009072A (en) 2004-02-09 2007-03-29 Human Genome Sciences Inc Albumin fusion proteins.
CN1950078A (en) * 2004-06-11 2007-04-18 诺和诺德公司 Counteracting drug-induced obesity using glp-1 agonists
EP3095456A1 (en) * 2005-11-04 2016-11-23 Glaxosmithkline LLC Methods for administering hypoglycemic agents
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators

Also Published As

Publication number Publication date
TWI430806B (en) 2014-03-21
AR062775A1 (en) 2008-12-03
US20100009910A1 (en) 2010-01-14
BRPI0716765A2 (en) 2013-09-24
JP5524620B2 (en) 2014-06-18
WO2008033888A2 (en) 2008-03-20
JP2010503697A (en) 2010-02-04
US8338369B2 (en) 2012-12-25
KR101472601B1 (en) 2014-12-15
EP2073834A2 (en) 2009-07-01
WO2008033888A3 (en) 2008-10-16
MY149911A (en) 2013-10-31
MA30768B1 (en) 2009-10-01
AU2007296499B2 (en) 2013-05-02
IL197448D0 (en) 2011-08-01
NZ575419A (en) 2011-11-25
CL2007002634A1 (en) 2008-05-16
EA017159B1 (en) 2012-10-30
JP5753924B2 (en) 2015-07-22
TW200824706A (en) 2008-06-16
CR10684A (en) 2009-04-28
EA200970274A1 (en) 2009-08-28
JP2014148524A (en) 2014-08-21
US20140066371A1 (en) 2014-03-06
CA2662622A1 (en) 2008-03-20
ES2442869T3 (en) 2014-02-14
PE15282012A1 (en) 2012-12-12
JO2945B1 (en) 2016-03-15
CA2662622C (en) 2017-01-17
MX2009002863A (en) 2009-03-30
SG10201501749WA (en) 2015-05-28
CN103705911A (en) 2014-04-09
ZA200901548B (en) 2010-02-24
KR20090059155A (en) 2009-06-10
AU2007296499A1 (en) 2008-03-20
AU2007296499C1 (en) 2013-09-12
EP2073834A4 (en) 2010-11-03
SG174770A1 (en) 2011-10-28
IL197448A (en) 2013-06-27
EP2073834B1 (en) 2013-10-23
US20130005652A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
RU2484097C2 (en) Method for treatment of diseases related to masp-2-dependent activation of complement (versions)
Rajendran et al. Efficient inhibition of the Alzheimer's disease β-secretase by membrane targeting
ES2486675T3 (en) Oxyntomodulin peptide analogue
NO20071419L (en) Polypeptides with altered effector function
RU2404806C2 (en) Extension of time to progression of disease or lifetime of oncologic patients with application of her dimerisation inhibitors
CY1111354T1 (en) Recommendations INHIBITOR ddp iv
GT200500179A (en) synergists anthranilamide agent mixtures for controlling invertebrate pests
CL2007001994A1 (en) Compounds derived from nitrogen heterocycles comprising phosphonate and phosphinate, glucokinase activators; pharmaceutical composition that comprises; and use of the compounds in the treatment of diabetes, hyperglycemia, hyperinsulinemia, cancer, dementia, obesity, among others.
MX2007010113A (en) Aprotinin polypeptides for transporting a compound across the blood-brain barrier.
EA201001680A1 (en) And oxazole compounds benzolsulfonamidtiazola
PE04582007A1 (en) pharmaceutical composition comprising 2 - [[6- (3R) -3-amino-1-piperidinyl] -3,4-dihydro-3-methyl-2,4-dioxo-1 (2H) -pyrimidinyl] methyl] -benzonitrile as dipeptidyl peptidase inhibitor
CL2007003552A1 (en) pyrimidine derivatives and pyridine compounds; pharmaceutical composition comprising said compound; and use of the compound for treating a cell proliferative disorder.
EA201001801A1 (en) Agonists mixed action based on glucose-insulinotropic peptide for the treatment of metabolic disorders and obesity
EA200870409A1 (en) Pi3 kinase antagonists
UY29983A1 (en) Derivatives of 4-amino-substituted pyrrolotriazine useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
CY1108467T1 (en) Configurations and methods for stabilizing transthyretinis and prevented esfalmenis FOLDING transthyretinis
ECSP045094A (en) Peptides which act as receptor agonists as GLP-1 and glucagon receptor antagonists and their use methods pharmacological
CR10530A (en) anti-dlla4 antibodies and methods that use
CY1107752T1 (en) Usage of exendin and their FIGHTERS for the treatment of diabetes sakcharodous PREGNANCY
WO2009058734A4 (en) Compounds exhibiting glucagon antagonist and glp-1 agonist activity
CY1113318T1 (en) Free of zinc and depleted in zinc INSULIN workshop preparations with improved stability
EA201270467A1 (en) Polycyclic compounds as antagonists of the lysophosphatidic acid receptors
UY29504A1 (en) Antibodies directed against the beta amyloid peptide and methods using the same.
ECSP064643A (en) Fusion proteins of glp-1
CY1111530T1 (en) CRYSTAL FORMS hydrochloride (-) - (1r, 2r) -3- (3-dimethylamino-1-ethyl-2-methylpropyl) -fainolis for use as active ingredient in PHARMACEUTICAL COMPOSITIONS

Legal Events

Date Code Title Description
FC Refusal